In silico disease modeling and clinical trial simulation is transforming drug R&D by accelerating and de-risking clinical development. Novadiscovery’s JINKO is a globally leading clinical trial simulation platform to predict drug efficacy and optimize clinical trial development.
Sanofi’s investment will accelerate the development of JINKO; facilitate the Company’s expansion into the US; and develop COVID-19 disease model to support Sanofi’s vaccine and therapeutic efforts.
We look forward to working closely with Sanofi to further test and enhance JINKO’s power and expand our understanding of how to best serve our customers’ needs. – Francois-Henri Boissel, CEO of Novadiscovery.
Access their full press release here